Radiomic-Based Method Predicts Recurrent Glioblastoma Outcome

Share this content:
Radiomic-Based Method Predicts Recurrent Glioblastoma Outcome
Radiomic-Based Method Predicts Recurrent Glioblastoma Outcome

TUESDAY, Oct. 11, 2016 (HealthDay News) -- A radiomic-based approach can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior to bevacizumab treatment, according to a study published online Oct. 10 in Clinical Cancer Research.

Philipp Kickingereder, M.D., from the University of Heidelberg Medical Center in Germany, and colleagues automatically extracted and analyzed 4,842 quantitative magnetic resonance imaging features from the multiparametric tumors of 172 patients with recurrent glioblastoma prior to bevacizumab treatment (allocated in a 2:1 ratio to a discovery and validation set). Radiomic features of patients in the discovery set were subjected to a supervised principal component (superpc) analysis leveraging a high throughput approach in order to develop a prediction model for stratifying treatment outcome to antiangiogenic therapy (progression-free [PFS] and overall survival [OS]).

The researchers found that patients in the discovery set were stratified into low- or high-risk groups for PFS and OS based on the superpc predictor (hazard ratios, 1.60 and 2.14, respectively). The stratification was validated in the validation set (hazard ratios, 1.85 and 2.60, respectively).

"Our radiomic-based superpc signature emerges as a putative imaging biomarker for the identification of patients who may derive the most benefit from antiangiogenic therapy, advances the knowledge in the noninvasive characterization of brain tumors, and stresses the role of radiomics as a novel tool for improving decision support in cancer treatment at low cost," the authors write.

One author disclosed financial ties to Genentech and Roche; Genentech manufactures bevacizumab.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

ASCO: Moderate Activity Tied to Longer Survival in Advanced CRC

ASCO: Moderate Activity Tied to Longer Survival in ...

Patients only appeared to derive benefit from moderate -- not vigorous -- activity

Number of Infants Born to Women Using Opioids Up Sharply

Number of Infants Born to Women Using Opioids ...

Few treatment programs deal with substance abuse in expectant moms, federal report says

Hypertension Onset After Age 80 May Protect Against Dementia

Hypertension Onset After Age 80 May Protect Against ...

Association independent of antihypertensive medication use

is free, fast, and customized just for you!

Already a member?

Sign In Now »